Proteomic signatures of radioresistance: Alteration of inflammation, angiogenesis and metabolism-related factors in radioresistant oesophageal adenocarcinoma.
Adenocarcinoma
/ metabolism
Apoptosis
Cell Line, Tumor
Chemoradiotherapy, Adjuvant
Esophageal Neoplasms
/ metabolism
Gene Ontology
Humans
Inflammation
/ metabolism
Mitochondrial Proteins
/ metabolism
Neoadjuvant Therapy
Neovascularization, Pathologic
/ metabolism
Protein Interaction Mapping
Proteome
Radiation Tolerance
/ genetics
Signal Transduction
Angiogenesis
Biomarkers
Cancer metabolism
Inflammation
Proteomics
Radioresistance
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
01
2021
revised:
09
04
2021
accepted:
11
04
2021
pubmed:
22
4
2021
medline:
31
12
2021
entrez:
21
4
2021
Statut:
ppublish
Résumé
The clinical management of locally advanced oesophageal adenocarcinoma (OAC) involves neoadjuvant chemoradiotherapy (CRT), but as radioresistance remains a major clinical challenge, complete pathological response to CRT only occurs in 20-30% of patients. In this study we used an established isogenic cell line model of radioresistant OAC to detect proteomic signatures of radioresistance to identify novel molecular and cellular targets of radioresistance in OAC. A total of 5785 proteins were identified of which 251 were significantly modulated in OE33R cells, when compared to OE33P. Gene ontology and pathway analysis of these significantly modulated proteins demonstrated altered metabolism in radioresistant cells accompanied by an inhibition of apoptosis. In addition, inflammatory and angiogenic pathways were positively regulated in radioresistant cells compared to the radiosensitive cells. In this study, we demonstrate, for the first time, a comprehensive proteomic profile of the established isogenic cell line model of radioresistant OAC. This analysis provides insights into the molecular and cellular pathways which regulate radioresistance in OAC. Furthermore, it identifies pathway specific signatures of radioresistance that will direct studies on the development of targeted therapies and personalised approaches to radiotherapy.
Identifiants
pubmed: 33882379
pii: S2468-2942(21)00074-5
doi: 10.1016/j.ctarc.2021.100376
pii:
doi:
Substances chimiques
Mitochondrial Proteins
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100376Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.